Scot Richard Mente

This inventor holds 29 USPTO granted patents and 16 published patent applications, plus 9 CIPO patents and 10 EPO patents, primarily in Heteroaromatic Compounds. Top assignees: Pfizer Corporation, Nuvalent, Inc.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Scot Richard Mente. Retrieved from https://idiyas.com/inventor/scot-richard-mente

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 (Patent Applications = 16)

% Patents Active = 82.8

CIPO Patents = 9 (Patent Applications = 4)

EPO Patents = 10 (Patent Applications = 16)

Average Co-Inventor Count = 9.2

ph-index = 5

Forward Citations = 79(Granted Patents)

Location History:

Mystic, CT (US) (2013)
Arlington, MA (US) (2014 - 2024)
Cambridge, MA (US) (2024)

Company Filing History:

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

Chemotherapeutic Agents

Dopamine D1 Ligands

Heteroaromatic Compounds

Pyrrolopyridine Modulators

RORC2 Modulators

Indole Modulators

Fused Pyridine Compounds

Cancer Treatment

EGFR Mutations

Kappa Opioid Ligands

Amino-Substituted Heteroaryls

Macrocyclic Ethers

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12275742 - Heteroaromatic macrocyclic ether chemotherapeutic agents (2025-04-14),

2. 12054498 - Heteroaromatic macrocyclic ether chemotherapeutic agents (2024-08-06),

3. 12037346 - Amino-substituted heteroaryls for treating cancers with EGFR mutations (2024-07-16),

4. 11964961 - Heteroaromatic compounds and their use as dopamine D1 ligands (2024-04-23),

5. 11667649 - Heteroaromatic macrocyclic ether chemotherapeutic agents (2023-06-06),

6. 11542278 - Heteroaromatic macrocyclic ether chemotherapeutic agents (2023-01-03),

7. 11014909 - Heteroaromatic compounds and their use as dopamine D1 ligands (2021-05-25),

8. 10696658 - Heteroaromatic compounds and their use as dopamine D1 ligands (2020-06-30),

9. 10426135 - Methyl- and trifluromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof (2019-10-01),

10. 10421744 - Heteroaromatic compounds and their use as dopamine D1 ligands (2019-09-24),

11. 10385036 - Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof (2019-08-20),

12. 10336748 - Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof (2019-07-02),

13. 10316021 - Heteroarylphenoxy benzamide kappa opioid ligands (2019-06-11),

14. 10227346 - Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof (2019-03-12),

15. 10093655 - Heteroaromatic compounds and their use as dopamine D1 ligands (2018-10-09),

Title: Scot Richard Mente: Innovator in Cancer Treatment

Introduction

Scot Richard Mente, an accomplished innovator based in Arlington, MA, has made significant contributions to the field of medicinal chemistry through his extensive portfolio of 28 patents. His work primarily focuses on developing novel chemotherapeutic agents aimed at improving cancer treatment.

Latest Patents

Among his latest patents, Scot has developed pioneering compounds such as heteroaromatic macrocyclic ether chemotherapeutic agents. These compounds are designed to treat or prevent cancer, providing new therapeutic avenues for patients. Another key patent involves amino-substituted heteroaryls, which are also targeted toward treating cancers with EGFR mutations. These discoveries reflect Scot's commitment to advancing cancer therapies and his ability to create valuable pharmaceutical compositions.

Career Highlights

Throughout his career, Scot Richard Mente has collaborated with leading companies such as Pfizer Corporation and Nuvalent, Inc. His experience in these prestigious organizations has equipped him with a comprehensive understanding of the pharmaceutical landscape, further enhancing his innovative capabilities.

Collaborations

Scot has had the pleasure of working alongside remarkable colleagues, including Jennifer Elizabeth Davoren and Amy Beth Dounay. These collaborations have allowed for a rich exchange of ideas and contributed to the success of their innovative projects.

Conclusion

In summary, Scot Richard Mente has positioned himself as a key player in the realm of cancer research, with a robust array of patents that showcase his inventive spirit and dedication to improving patient outcomes. His work continues to inspire future generations of inventors and researchers in the field of medicinal chemistry.

Profile summary based on public USPTO records.